Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 170,000 shares at $64.51 ($10.9M) on 2025-12-17, disclosed to the SEC on 2025-12-19.
Seasonal sale ($10.9M) by Chief Executive Officer — this insider has traded ARWR in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $63.55 | 46,287 | $2.9M | 27.0% |
| 2 | $63.55 | 46,287 | $2.9M | 27.0% |
| 3 | $64.51 | 35,750 | $2.3M | 21.2% |
| 4 | $64.51 | 35,750 | $2.3M | 21.2% |
| 5 | $65.53 | 982 | $64K | 0.6% |
| 6 | $65.53 | 982 |
| $64K |
| 0.6% |
| 7 | $66.30 | 1,981 | $131K | 1.2% |
| 8 | $66.30 | 1,981 | $131K | 1.2% |
| Total | $64.04 avg | 170,000 | $10.9M | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |
| ARWR | SELL | 2025-04-11 | $1.9M | — | Filing → |